{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T06:08:15Z","timestamp":1788761295043,"version":"build-2803163510"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chronic inflammatory rheumatic diseases, such as ankylosing spondylitis, psoriatic arthritis, reactive arthritis, and enteropathic arthritis, are collectively referred to as spondyloarthropathies (SpA). However, Real-world evidence on the effectiveness and safety of ixekizumab in spondyloarthropathies remains limited, particularly in diverse populations outside clinical trial settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>This study aimed to evaluate patient demographics, treatment outcomes, drug survival, and safety profile of ixekizumab in patients with SpA in a real-world clinical setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study at a tertiary care hospital in Riyadh, Saudi Arabia, from January 2018 to December 2024. Patients aged \u226514 years with SpA who received ixekizumab were included. The primary outcomes included drug survival, treatment discontinuation rates, and reasons for discontinuation. Kaplan-Meier survival analysis and Cox proportional hazards regression were performed to identify the predictors of treatment discontinuation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 93 patients (mean age 44.2\u00a0\u00b1\u00a013.2 years, 60.2% female), psoriatic arthritis spectrum disorders predominated (71.0%), followed by ankylosing spondylitis (23.7%). Most patients (87.1%) had prior biologic exposure, with ixekizumab used predominantly as a second-line therapy (59.1%). Drug survival rates were 69.9% at 12 months and 43.0% at 24 months, with a median survival of 23.0 months (95% CI: 19.5-26.5). The overall discontinuation rate was 34.4%, primarily due to lack of efficacy (59.4%) and adverse events (18.8%). Treatment-emergent adverse events occurred in 7.5% of patients, with no serious adverse events reported. Disease type significantly influenced drug survival (p = 0.018), with psoriatic arthritis showing superior retention compared with ankylosing spondylitis (77.8% vs. 60.0% at 12 months). Multivariate analysis identified third-line or later therapy (HR 2.58, 95% CI 1.04-6.40, p = 0.041) and the presence of treatment-emergent adverse events (HR 9.86, 95% CI 3.42-28.41, p &amp;lt; 0.001) as independent predictors of discontinuation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Ixekizumab demonstrated acceptable drug survival and safety profiles in real-world patients with spondyloarthritis, with differential effectiveness across disease subtypes. Earlier treatment initiation and proactive management of adverse events may optimize treatment outcomes, supporting personalized therapeutic approaches for spondyloarthropathy management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1924119","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T05:33:28Z","timestamp":1788759208000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world drug survival and treatment outcome of ixekizumab in patients with spondyloarthropathies"],"prefix":"10.3389","volume":"17","author":[{"given":"Lamia","family":"AL-Awuad","sequence":"first","affiliation":[{"name":"Pharmaceutical Care Services, Prince Mohammed bin Abdulaziz Hospital","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munifah","family":"AL-Shammari","sequence":"additional","affiliation":[{"name":"King Abdulaziz Medical City, Pharmaceutical Care Services, Ministry of National Guard Health Affairs","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada","family":"Al-Dhayyan","sequence":"additional","affiliation":[{"name":"King Abdulaziz Medical City, Pharmaceutical Care Services, Ministry of National Guard Health Affairs","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulrahman","family":"Alturaiki","sequence":"additional","affiliation":[{"name":"King Abdulaziz Medical City, Pharmaceutical Care Services, Ministry of National Guard Health Affairs","place":["Riyadh, Saudi Arabia"]},{"name":"College of Pharmacy, King Saud Bin Abdulaziz University for Health Sciences","place":["Riyadh, Saudi Arabia"]},{"name":"King Abdullah International Medical Research Center","place":["Riyadh, Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.5312\/wjo.v2.i12.107","article-title":"Classification criteria for spondyloarthropathies","volume":"2","author":"Akgul","year":"2011","journal-title":"World J Orthop"},{"key":"B2","unstructured":"The Worldwide Prevalence of Spondyloarthritis"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0288561","article-title":"Temporal trends in the disease burden of osteoarthritis from 1990 to 2019, and projections until 2030","volume":"18","author":"Chen","year":"2023","journal-title":"PloS One"},{"key":"B4","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s11926-019-0844-7","article-title":"Current unmet needs in spondyloarthritis","volume":"21","author":"Poddubnyy","year":"2019","journal-title":"Curr Rheumatol Rep"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-024-01134-z","article-title":"Year in review in axial spondyloarthritis clinical research and guidelines: SPARTAN 2023 annual meeting proceedings","volume":"26","author":"Dubreuil","year":"2024","journal-title":"Curr Rheumatol Rep"},{"key":"B6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/ard-2022-223296","article-title":"ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update","volume":"82","author":"Ramiro","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B7","doi-asserted-by":"publisher","first-page":"178","DOI":"10.21037\/atm-23-195","article-title":"Efficacy and safety of IL inhibitors, TNF-\u03b1 inhibitors, and JAK inhibitors in patients with ankylosing spondylitis: a systematic review and Bayesian network meta-analysis","volume":"11","author":"Tian","year":"2023","journal-title":"Ann Transl Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)02151-2","article-title":"Driving down the cost of biologics: lessons from a nationalised health-care system","volume":"404","author":"Russell","year":"2024","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2024.103638","article-title":"Treatment strategies for spondyloarthritis: implementation of precision medicine \u2013 or \u201cone size fits all\u201d concept","volume":"23","author":"Proft","year":"2024","journal-title":"Autoimmun Rev"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.reuma.2025.501872","article-title":"One-year retention rate of ixekizumab in patients with psoriatic arthritis and axial spondyloarthritis: real-world data from the BIOBADASER registry","volume":"21","author":"L\u00f3pez-Medina","year":"2025","journal-title":"Reumatol Cl\u00ednica"},{"key":"B11","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2147\/JIR.S100940","article-title":"Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A","volume":"9","author":"Liu","year":"2016","journal-title":"J Inflammation Res"},{"key":"B12","article-title":"Ixekizumab","author":"Preuss","year":"2025","journal-title":"StatPearls [Internet]."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31946-9","article-title":"Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 r","volume":"392","author":"van der Heijde","year":"2018","journal-title":"Lancet (London England)"},{"key":"B14","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0140-6736(19)32971-X","article-title":"Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial","volume":"395","author":"Deodhar","year":"2020","journal-title":"Lancet"},{"key":"B15","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1002\/art.40753","article-title":"Efficacy and safety of ixekizumab in the treatment of radiographic axial spondyloarthritis: sixteen-week results from a phase III randomized, double-blind, placebo-controlled trial in patients with prior inadequate response to or intolerance of tumor nec","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheumatol (Hoboken NJ)"},{"key":"B16","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13075-020-02388-5","article-title":"Ixekizumab, with or without concomitant methotrexate, improves signs and symptoms of PsA: week 52 results from Spirit-P1 and Spirit-P2 studies","volume":"23","author":"Combe","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"B17","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13075-019-1831-0","article-title":"Ixekizumab and complete resolution of enthesitis and dactylitis: integrated analysis of two phase 3 randomized trials in psoriatic arthritis","volume":"21","author":"Gladman","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"B18","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13075-023-03257-7","article-title":"Long-term safety of ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: a post-hoc analysis of final safety data from 25 randomized clinical trials","volume":"26","author":"Deodhar","year":"2024","journal-title":"Arthritis Res Ther"},{"key":"B19","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13075-020-2099-0","article-title":"Safety results of ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis","volume":"22","author":"Combe","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.221022","article-title":"Long-term safety and efficacy of ixekizumab in patients with axial spondyloarthritis: 3-year data from the COAST program","volume":"50","author":"Deodhar","year":"2023","journal-title":"J Rheumatol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11555","article-title":"Human leukocyte antigen B27-negative axial spondyloarthritis: what do we know","volume":"5","author":"Deodhar","year":"2023","journal-title":"ACR Open Rheumatol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-022-06490-8","article-title":"HLA-B27 as a predictor of effectiveness of treatment with TNF inhibitors in axial spondyloarthritis: data from the Swiss Clinical Quality Management Registry","volume":"42","author":"Fr\u00f6hlich","year":"2023","journal-title":"Clin Rheumatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15787","article-title":"Response to IL-17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein-coding and untranslated regions of the IL-17A gene: results from a multicentre study of four European psoriasis cohorts","volume":"34","author":"van Vugt","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev374","article-title":"Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databases","volume":"55","author":"Souto","year":"2015","journal-title":"Rheumatology"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2022.2082354","article-title":"Efficacy, safety, and drug survival of patients with psoriasis treated with IL-17 inhibitors - brodalumab, ixekizumab, and secukinumab: real-world data from the Czech Republic BIOREP registry","volume":"33","author":"Kojanova","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3390\/jpm14070716","article-title":"Retention rate of ixekizumab in psoriatic arthritis: a real-world study","volume":"14","author":"Bellis","year":"2024","journal-title":"J Pers Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14808","article-title":"Drug survival of ixekizumab, TNF inhibitors, and other IL-17 inhibitors in real-world patients with psoriasis: the Corrona Psoriasis Registry","volume":"34","author":"Lockshin","year":"2021","journal-title":"Dermatol Ther"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.11.015","article-title":"Comparison of real-world treatment patterns among patients with psoriasis prescribed ixekizumab or secukinumab","volume":"82","author":"Blauvelt","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/rap\/rkae018","article-title":"Real-world experience of IL-17Ai drug survival in a large cohort of axial spondyloarthritis and psoriatic arthritis","volume":"8","author":"Weddell","year":"2024","journal-title":"Rheumatol Adv Pract"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-002165","article-title":"Efficacy and safety of ixekizumab treatment in patients with axial spondyloarthritis: 2-year results from COAST","volume":"8","author":"Braun","year":"2022","journal-title":"RMD Open"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.221022","article-title":"Long-term safety and efficacy of ixekizumab in patients with axial spondyloarthritis: 3-year data from the COAST program","volume":"50","author":"Deodhar","year":"2023","journal-title":"J Rheumatol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-020-00442-x","article-title":"Drug survival of biologics in treating ankylosing spondylitis: a systematic review and meta-analysis of real-world evidence","volume":"34","author":"Yu","year":"2020","journal-title":"BioDrugs"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-024-02028-1","article-title":"Drug survival of IL-17 and IL-23 inhibitors for psoriasis: a systematic review and meta-analysis","volume":"84","author":"Thomas","year":"2024","journal-title":"Drugs"},{"key":"B34","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13075-020-02208-w","article-title":"Efficacy and safety of IL-17 inhibitors for the treatment of ankylosing spondylitis: a systematic review and meta-analysis","volume":"22","author":"Yin","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/2546161","article-title":"Short-term efficacy and safety of IL-17, IL-12\/23, and IL-23 inhibitors brodalumab, secukinumab, ixekizumab, ustekinumab, guselkumab, tildrakizumab, and risankizumab for the treatment of moderate to severe plaque psoriasis: a systematic review and network meta-analysis of randomized controlled trials","volume":"2019","author":"Bai","year":"2019","journal-title":"J Immunol Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-020-04970-3","article-title":"A systematic review and network meta-analysis of current and investigational treatments for active ankylosing spondylitis","volume":"39","author":"Deodhar","year":"2020","journal-title":"Clin Rheumatol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.03.048","article-title":"Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis","volume":"81","author":"Egeberg","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"697","DOI":"10.3349\/ymj.2023.0151","article-title":"Drug retention rate and factors associated with discontinuation of interleukin-17 inhibitors in patients with axial spondyloarthritis","volume":"64","author":"Kwon","year":"2023","journal-title":"Yonsei Med J"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-023-05289-3","article-title":"Ixekizumab therapy following secukinumab inadequate response in psoriatic arthritis: a case series focusing on axial disease","volume":"43","author":"Panagiotopoulos","year":"2023","journal-title":"Rheumatol Int"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.2147\/BTT.S326792","article-title":"Treatment with ixekizumab following secukinumab failure in patients with psoriatic arthritis: real-life experience from a resistant population","volume":"15","author":"Berman","year":"2021","journal-title":"Biologics"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1002\/art.23333","article-title":"The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study","volume":"59","author":"Heiberg","year":"2008","journal-title":"Arthritis Rheum"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215356","article-title":"The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies","volume":"78","author":"McGonagle","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.596086","article-title":"The IL-17\/IL-23 axis and its genetic contribution to psoriatic arthritis","author":"Vecellio","year":"2021","journal-title":"Front Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-018-8702-3","article-title":"The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis","volume":"55","author":"Blauvelt","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102760","article-title":"Exploring IL-17 in spondyloarthritis for development of novel treatments and biomarkers","volume":"20","author":"Groen","year":"2021","journal-title":"Autoimmun Rev"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N Engl J Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201933","article-title":"Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor \u03b1 inhibitor therapy: results from the Danish nationwide DANBIO registry","volume":"72","author":"Glintborg","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"B48","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13075-019-1908-9","article-title":"Biological treatment of ankylosing spondylitis: a nationwide study of treatment trajectories on a patient level in clinical practice","volume":"21","author":"Lindstr\u00f6m","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.2147\/ITT.S259126","article-title":"Anti-IL-17 agents in the treatment of axial spondyloarthritis","volume":"10","author":"Atzeni","year":"2021","journal-title":"ImmunoTargets Ther"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.129726","article-title":"Is ASDAS better than BASDAI as a measure of disease activity in axial psoriatic arthritis","volume":"69","author":"Eder","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.993057","article-title":"Adverse events associated with anti-IL-17 agents for psoriasis and psoriatic arthritis: a systematic scoping review","author":"Wang","year":"2023","journal-title":"Front Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa189","article-title":"Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials","volume":"59","author":"Genovese","year":"2020","journal-title":"Rheumatol (Oxford)"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-022-00743-9","article-title":"Safety of ixekizumab in adult patients with moderate-to-severe psoriasis: data from 17 clinical trials with over 18,000 patient-years of exposure","volume":"12","author":"Griffiths","year":"2022","journal-title":"Dermatol Ther (Heidelb)"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1924119\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T05:33:30Z","timestamp":1788759210000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1924119\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,7]]},"references-count":53,"alternative-id":["10.3389\/fimmu.2026.1924119"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1924119","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,7]]},"article-number":"1924119"}}